Chinese Biotechs Join COVID-19 Treatment Race With Repurposed Cancer Drugs
Chinese bioventures leap into the COVID cure fray as two little-known companies kick off clinical studies of androgen receptor antagonists in Brazil and the US.
You may also be interested in...
While new oral COVID-19 drugs are commanding the headlines, a little-known Chinese biotech is pushing ahead with an intravenous small molecule antiviral candidate now moving towards Phase II/III US trials, its CEO tells Scrip.
Brian Yang, Dexter Yan and guest speaker Kevin Grogan from the UK discuss Shanghai's latest policy to spur biopharma investment, the US House's recent draft bill to restrict bio service providers from China, and multinationals' strategies in China and views on Chinese innovation.
Only drugs awarded high points under a government-designated scoring method will benefit most from a new pricing scheme in China. The criteria include the products’ innovativeness in terms of pharmaceutical sciences, the clinical value for patients and clinical evidence from clinical studies.